-+ 0.00%
-+ 0.00%
-+ 0.00%

Stephens & Co. Maintains Overweight on 10x Genomics, Raises Price Target to $65

Benzinga·08/12/2026 16:21:09
Listen to the news
Stephens & Co. analyst Mason Carrico maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises the price target from $50 to $65.